Effects of Tocilizumab in COVID-19 patients: a cohort study

Christine Vu (christine.vu@jhsmiami.org)  
Jackson Memorial Hospital  https://orcid.org/0000-0003-0162-5101

Kailynn J Deronde  
Jackson Memorial Hospital

Ana D Vega  
Jackson Memorial Hospital

.Meshell Maxam  
Jackson Memorial Hospital

Gregory Holt  
University of Miami School of Medicine

Yoichiro Natori  
University of Miami School of Medicine

Jose Gonzales Zamora  
University of Miami School of Medicine

Veronica Salazar  
Jackson Memorial Hospital

Renata Boatwright  
Jackson Memorial Hospital

Stephen R Morris  
University of Miami School of Medicine

Daniela de Lima Corvino  
University of Miami School of Medicine

Anmary Fernandez Betances  
University of Miami School of Medicine

Leah Colucci  
University of Miami School of Medicine

James keegan  
University of Miami School of Medicine

Andy Lopez  
University of Miami School of Medicine

Andrew Hany Rezk  
University of Miami School of Medicine

Yvette Rodriguez
Research article

Keywords: coronavirus, COVID-19, tocilizumab, cytokine release syndrome

DOI: https://doi.org/10.21203/rs.3.rs-49532/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Due to the lack of proven therapies, we evaluated the effects of early administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab may help to mitigate the hyperinflammatory response associated with progressive respiratory failure caused by SARS-CoV-2.

Methods: A retrospective, observational study was conducted on hospitalized adults who received intravenous tocilizumab for COVID-19 between March 23, 2020 and April 10, 2020.

Results: Most patients were male (66.7%), Hispanic (63.3%) or Black (23.3%), with a median age of 54 years. Tocilizumab was administered at a median of 8 days (range 1-21) after initial symptoms and 2 days (range 0-12) after hospital admission. On the day of administration, the median PaO$_2$/FiO$_2$ was 166 (range 33-523) and 50 patients (83.3%) had ARDS. By day 30, 36 patients (60.0%) demonstrated clinical improvement, 9 (15.0%) died, 33 (55.0%) were discharged alive, and 18 (30.0%) remained hospitalized. Successful extubation occurred in 13 out of 29 patients (44.8%). Infectious complications occurred in 16 patients (26.7%) at a median of 10.5 days. There was an increase in PaO$_2$/FiO$_2$ and an initial reduction in CRP that was not sustained beyond day 10.

Conclusions: Majority of patients demonstrated clinical improvement and were successfully discharged from the hospital alive after receiving tocilizumab. Similar to previous studies, infectious complications were not uncommon. We observed a rebound effect with CRP, which may suggest the need for higher or subsequent doses to adequately manage cytokine storm. Based on our findings, we believe that tocilizumab may have a role in the treatment of COVID-19, however randomized controlled studies are urgently needed.

Background

The rapid spread of the novel coronavirus disease led to a pandemic since the first reported case in Wuhan, China in December 2019. The Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2 is responsible for 204,033 deaths in the United State as of September 27, 2020 [1]. In Florida, we have seen an increase in severe cases, which have accounted for over 14,000 deaths according to the Centers for Disease Control and Prevention [1].

COVID-19 is a rapidly progressing disease with hypoxemic respiratory failure as the primary cause of death [2]. Recent autopsy cases analyzing the etiology of severe lung injury in COVID-19 patients revealed histologic patterns of diffuse alveolar damage and perivascular T-cell infiltration in the presence of intracellular SARS-CoV-2 [3]. This severe lung injury is thought to be due to excessive immune upregulation in response to the virus, similar to what is seen in cytokine release syndrome (CRS) [4, 5]. Among the numerous cytokines that are released, interleukin-6 (IL-6) is thought to play a major role in causing acute respiratory distress syndrome (ARDS) [6, 7].
Tocilizumab, an antagonist of soluble IL-6 receptor, is now being evaluated for the management of COVID-19. Previously approved for the treatment of severe or life-threatening chimeric antigen receptor (CAR) T cell-induced CRS, its ability to down regulate the immune system may have positive implications for COVID-19 [8, 9]. Studies have demonstrated tocilizumab to be associated with improvements in inflammatory markers, clinical response, and survival [10-18]. During an unprecedented time when proven effective therapies are lacking, we aimed to describe our real-life experience using tocilizumab for COVID-19.

Methods

Setting

We retrospectively analyzed hospitalized patients who received intravenous (IV) tocilizumab for COVID-19 within our large health care system in Miami, Florida between March 23, 2020 and April 10, 2020. Our health system is comprised of three acute care facilities with over 2,500 licensed beds, including 150 adult intensive care unit beds. This study was approved by the University of Miami Institutional Review Board and Jackson Health System Clinical Research Review Committee (CRRC) and a waiver of informed consent was granted.

Tocilizumab process

Tocilizumab was restricted to the Antimicrobial Stewardship Program (ASP) with pre-approval authorization for the management of highly suspected or laboratory-confirmed SARS CoV-2 infection. The approval process occurred in real-time seven days a week and required multidisciplinary discussions between infectious diseases physicians, pulmonary/critical care physicians, hospitalists, and pharmacists. Since February 2020, we created an institution-specific clinical protocol to guide physicians on when to consider COVID-19 investigational agents. For tocilizumab, we recommended use if the following criteria was met: requiring ≥4 liters of nasal cannula to maintain a SpO2 >93%, signs of clinical deterioration, and elevations in at least 2 inflammatory markers to suggest cytokine storm. These included interleukin-6 >40 pg/ml, C-reactive protein >10 mg/dL, lactate dehydrogenase > 350 U/L, ferritin >1000 ng/mL, D-dimer >1 mcg/ml (see Appendix 1 supplemental material) [17]. Tocilizumab was discouraged in patients with concomitant bacterial infections, baseline elevations of ALT or AST above 5 times the upper limit of normal (ULN), baseline platelet count <100 x10⁹/L, baseline absolute neutrophil count < 1.5 x10⁹/L, and history of diverticular disease or gastrointestinal perforation. However, exceptions were made if possible benefit outweighed risks. We recommended flat dosages of 400 mg (30-100 kg) and 600 mg (>100 kg) based on the limited evidence and resource allocations during that time [12, 20].

Study participants

Eligible patients were hospitalized adults (age ≥18 years) with suspected or laboratory-confirmed SARS-CoV-2 infection and received at least one dose of IV tocilizumab. Any patients with high clinical suspicion
for COVID-19 and later confirmed as negative by qualitative real-time PCR were excluded. All patients received standard of care treatment for COVID-19 based on our institution-specific protocol, which at the time included hydroxychloroquine. Other therapies such as methylprednisolone, intravenous immunoglobulin, and convalescent plasma were recommended on a case-by-case basis. Data to support dexamethasone was published after the completion of our study.

Outcomes and definitions

The electronic medical record was retrospectively reviewed to collect data on day -1, 0, 1, 2, 3, 4, 5, 7, 10, 14 and 30 relative to tocilizumab administration. We recorded laboratory and respiratory parameters, clinical improvement (defined as ≥2-point reduction on the WHO COVID-19 ordinal scale), all-cause mortality, proportion of patients discharged, proportion of patients requiring oxygen support, proportion of patients requiring intensive care unit (ICU) care, proportion of patients successfully extubated (defined as not requiring re-intubation within the same hospitalization), and infectious complications within 30 days of tocilizumab. Infectious complications were defined as having a positive culture from a sterile site and treated by the medical team, we excluded suspected colonization or contamination. Oxygenation was assessed by calculating PaO$_2$/FiO$_2$ from the morning arterial blood gas (ABG) and corresponding FiO$_2$. For infrequent cases when an ABG was not available to measure the PaO$_2$, we used an estimation formula based on the corresponding SpO$_2$, S/F = 64 + 0.84 * PaO$_2$/FiO$_2$ [19]. Acute respiratory distress syndrome (ARDS) was defined according to the Berlin Criteria [22]. Patient severity was assessed using the WHO ordinal scale for clinical improvement [23].

Statistical analysis

Descriptive statistics were used to analyze the data. Continuous variables were expressed as median and range while categorical variables were expressed as counts and percentages.

Results

A total of 63 patients were treated with tocilizumab during our study period. Three patients were excluded as they were empirically treated as “patients under investigation” per the US Centers for Disease Control and Prevention criteria but later found to have a negative qualitative real-time PCR as well as an alternative diagnosis of infection. Patient characteristics are described in Table 1. Most patients were male (66.7%), Hispanic (63.3%) or Black (23.3%), with a median age was 54 years old (range 26-87). The most common comorbidities were hypertension (53.3%), obesity (38.3%), and diabetes (25.0%). The median time from symptom onset to hospital admission was 6 days (range 1-14). The median time to receiving tocilizumab from hospital admission was 2 days (range 0-12). The patients who died received tocilizumab at a median time similar to the entire cohort, which was 8 days from symptom onset. A majority of patients received hydroxychloroquine (86.7%). Of the 32 patients that received steroids, 28.1% received >5 mg/kg/day of methylprednisolone equivalents, 15.6% received 2-5 mg/kg/day of methylprednisolone equivalents, and 56.3% received ≤2mg/kg/day of methylprednisolone equivalents.
The median weight for our cohort was 91.5 kg (range 59-182) and the average dose of tocilizumab administered was 4.75 mg/kg. Forty-seven patients received a flat dose of 400 mg and 13 patients received 600 mg. Only 3 patients received a second dose of tocilizumab.

The clinical presentation of patients on the day of tocilizumab administration are described in Table 2. For disease severity, most patients scored a 4 (40.0%) or 7 (28.3%) based on the WHO COVID-19 ordinal scale. Most patients received oxygen supplementation via nasal cannula (31.7%) or invasive mechanical ventilation (40.0%). The median PaO$_2$/FiO$_2$ was 166 (range 33-523) and fifty patients (83.3%) had ARDS. For abnormal laboratory values, we observed neutrophilia, lymphopenia, elevated neutrophil-to-lymphocyte ratio, elevated aspartate aminotransferase (AST), along with increased interleukin-6 (IL-6), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), lactate dehydrogenase (LDH), ferritin, procalcitonin, D-dimer, and troponin.

Outcomes for patients within 30 days from receiving tocilizumab are summarized in Table 3. A total of 36 patients (60.0%) achieved clinical improvement, 9 patients (15.0%) died, 33 patients (55.0%) were discharged from the hospital alive, and 18 patients (30.0%) remained hospitalized at 30 days. Fifty-two patients (86.7%) required ICU care of which twenty-nine (48.3%) were on invasive mechanical ventilation. Thirteen patients (44.8%) were successfully extubated within the 30 days. We identified 29 cultures in 16 patients (26.7%) who developed infectious complications post-tocilizumab. The median time to first infection was 10.5 days (range 2-28). The most common types of infection were respiratory (48.3%) and bacteremia (44.8%) (see Appendix 3 supplemental material). We describe additional clinical measures pertaining to organ complications, modes of ventilation, and SOFA scores in the Appendix 2 supplemental material.

The progression of select laboratory and respiratory parameters within 14 days of tocilizumab are displayed in Figure 1 and Figure 2. We observed an initial reduction in CRP; however levels began to rise after day 10. The opposite effect was seen with D-dimer. We saw an increase in IL-6 as expected. Additionally, there were improvements in both lymphopenia and oxygenation as assessed by PaO$_2$/FiO$_2$. No clear trends were seen for lactate dehydrogenase, procalcitonin, troponin, or neutrophil-to-lymphocyte ratio (NLR).

**Discussion**

During the rapidly spreading pandemic, physicians were faced with the challenge of recommending investigational agents for the treatment of COVID-19. At our site, we chose to provide tocilizumab in patients with suspected CRS in order to reduce elevated IL-6 levels, which has been associated with ICU admission, ARDS, and death [7]. The first dose of tocilizumab was given at a median of two days from hospital admission and a majority of patients (66.7%) received tocilizumab while not on invasive mechanical ventilation. We believed that early administration of tocilizumab could help to prevent progression to invasive mechanical ventilation. This has also been suggested by preliminary findings
from two randomized clinical trials [24, 25]. In our cohort, 9 out of 31 patients who received tocilizumab while not intubated eventually progressed to invasive mechanical ventilation.

Our patients presented with typical manifestations of COVID-19 and had signs and symptoms of cytokine release syndrome on the day of tocilizumab administration. Similar to previous reports, patients with more severe disease demonstrated transaminitis, along with abnormal blood counts such as neutrophilia, lymphopenia, and elevated NLR ratio [5, 25]. After receiving tocilizumab, we observed reductions in CRP; however, unlike other studies, this effect was not sustained [11-13]. We believe our eventual rise in CRP beyond day 10 correlates with tocilizumab’s elimination half-life of 11 to 13 days [27]. Sciascia et al. reported a sustained decrease in CRP for 14 days, but a large proportion of their patients received a second dose of tocilizumab (91% vs. 5%) along with higher doses (8 mg/kg). As such, tocilizumab’s effect on CRP may be dose-dependent and that re-dosing after 10 days may be warranted. When analyzing other laboratory parameters, there were improvements in both ferritin and absolute lymphocyte count, which is in agreement to previous reports [12, 13]. And although repeat IL-6 levels were only available for one third of our patients, we observed an increase shortly after tocilizumab administration; previous studies have explained this effect to be from competitive binding of tocilizumab to the IL-6 receptor, leaving more free IL-6 to accumulate in the serum [28]. Furthermore, we observed an increase in D-dimer that peaked at day seven, and then decreased. Some have correlated D-dimer with the risk of developing pulmonary embolism in COVID but this was not investigated in our study. No clear trends were seen for LDH or procalcitonin, suggesting that these markers are non-specific to COVID-19.

There are mixed results on oxygenation progression after tocilizumab administration in COVID-19 patients. Both Xu et al. and Capra et al. reported improvements in oxygenation in a majority of their patients but Rimland et al. observed no improvement [12, 14, 29]. In our study, we observed an overall increase in PaO$_2$/FiO$_2$ within 14 days of tocilizumab. However, it is unclear whether this improvement is due to tocilizumab or reflects the natural course of ARDS. When compared to Sciascia et al., our oxygenation improvement was not as impressive and could be due to having more patients on invasive mechanical ventilation (48.2% vs. 7.9%) [13]. Furthermore, we observed successful extubation in 13 out of 29 patients (44.8%) within 30 days of tocilizumab administration. Rates of extubation for COVID-19 have only been recorded in a small study where 2 out of 3 patients were successfully extubated after tocilizumab [11].

We observed 36 patients (60.0%) achieving at least a 2-point reduction in the WHO COVID-19 ordinal scale and 33 patients (55.0%) discharged alive within the 30 days of receiving tocilizumab. Our discharge rate was higher than the 18% reported by Rimland et al. but lower than the 63% reported by Campochiaro et al. [29, 30]. We observed a 30-day mortality rate of 15%, which is comparable to prior studies ranging between 13% and 27% [11, 13, 15-17, 29-30]. So far, only a few studies have compared mortality associated with tocilizumab versus standard of care in COVID-19 patients. Campochiaro et al. found no significant difference in 28-day mortality (15% vs. 22%, p=0.15) whereas Somers et al. identified a 45% reduction in the risk of death (HR 0.55, 95% CI 0.33-0.90) in mechanically ventilated patients [15, 30]. Guaraldi et al. also found tocilizumab to be associated with a reduced risk of all-cause mortality after
adjusting for age, sex, recruiting center, duration of symptoms, and SOFA score (HR 0.38, 95% CI 0.17-0.83) [17]. And more recently, Biran et al. noted an association between receiving tocilizumab and decreased hospital-related mortality (HR 0.64, 95% CI 0.47-0.87) [18]. Overall, these findings suggest a possible mortality benefit with tocilizumab, however it is important to recognize that many patients also received steroids, which has been independently associated with improved survival [32].

Historically, tocilizumab has been associated with secondary infections. In the rheumatoid arthritis population, a meta-analysis conducted by Navarro et al. found a 37.5% infection incidence in the tocilizumab group compared to 33.8% in the placebo group [33]. In the chimeric antigen receptor modified (CAR) T population, 133 patients who received tocilizumab had an infection incidence of 23% within 90 days [30]. In our COVID-19 study, we identified a higher proportion of infections within a shorter amount of time: 26.7% within 30 days. Guaraldi also observed more infections in patients who received tocilizumab compared to standard of care (13% vs. 4%, p<0.0001) [17]. Kimmig et al. found an even higher incidence of infection of 64.2% but they had a longer follow-up time at 8 weeks and a broader definition for infection to also capture highly suspected infections rather than just confirmed [31]. Another study by Somers et al. found a two-fold higher incidence of infections in patients who received tocilizumab at 28 days (54% vs. 26%, p<0.001) but more patients in the tocilizumab arm received steroids [15]. To date, the only study who excluded steroid use reported a 13% infection incidence at 28 days [34]. Taken altogether, tocilizumab may increase the risk of infections, however better designed studies that take into account potential confounders are needed.

Our study had several limitations. First, it was a retrospective study with a small sample size. Second, the flat doses of 400 and 600 mg for tocilizumab could have resulted in lower than optimal doses if extrapolating from FDA-approved (8 mg/kg) doses for CAR T cell-induced CRS [8]. Third, many patients received concomitant therapies that could impact clinical outcomes, such as IVIG and steroids. Fourth, many of our infections were diagnosed based on tracheal aspirates because bronchoscopies were infrequent at the time. The quality of the culture, in addition to the critical nature of the patient made diagnosis of pneumonia particularly challenging. Fifth, the study end point of 30 days precluded us from identifying long-term infectious complications post-tocilizumab. Lastly, this study was descriptive and not aimed to investigate predisposing risk factors for infectious complications or to determine tocilizumab efficacy.

**Conclusion**

In this study, we demonstrated the effects of off-label tocilizumab in 60 patients with COVID-19. We primarily used tocilizumab in patients presenting with signs of cytokine release syndrome and acute respiratory distress syndrome. Many patients achieved clinical improvement and were eventually discharged from the hospital. Interestingly, we observed a rebound effect with C-reactive protein suggesting the need for higher or subsequent doses. Similar to prior studies, infectious complications after tocilizumab were not uncommon. Our results highlight the need for future studies investigating the safety, efficacy, and optimal timing of tocilizumab in COVID-19 patients.
Abbreviations

COVID-19: Coronavirus Disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; CRS: Cytokine release syndrome; IL-6: Interleukin-6; ARDS: Acute respiratory distress syndrome; CAR: Chimeric antigen receptor; IV: intravenous; CRRC: Clinical Research Review Committee; ASP: Antimicrobial Stewardship program; SpO2: Saturation of peripheral oxygen; PCR: polymerase chain reaction; WHO: World Health Organization; ICU: Intensive care unit; PaO2/FiO2: Partial pressure of oxygen/fraction of inspired oxygen; ABG: Arterial blood gas; AST: Aspartate aminotransferase; CRP: C-reactive protein, ESR: Erythrocyte sedimentation rate, LDH: Lactate dehydrogenase; NLR: Neutrophil-to-lymphocyte ratio

Declarations

Acknowledgements

We would like to thank all the health care providers who have risked their lives caring for COVID-19 patients.

Authors’ contributions

CA: Conceptualization, Methodology, Formal analysis, Data curation, Writing – Original Draft, Writing-Review & Editing, Visualization. KJD: Conceptualization, Methodology, Data curation, Writing – Original Draft, Writing- Review & Editing. ADV: Conceptualization, Methodology, Data curation, Writing – Original Draft, Writing- Review & Editing. MM: Conceptualization, Methodology, Data curation, Writing – Original Draft, Writing- Review & Editing. GH: Conceptualization, Methodology, Formal analysis, Writing- Review & Editing. YH: Conceptualization, Methodology, Writing- Review & Editing. JGZ: Conceptualization, Methodology, Writing- Review & Editing. VS: Data curation, Writing- Review & Editing. RB: Data curation, Writing- Review & Editing. SRM: Conceptualization, Investigation, Writing- Review & Editing. DC: Investigation. AFB: Investigation. LH: Investigation. JK: Investigation. AL: Investigation. AHR: Investigation. YR: Investigation. Susanne Doblecki: Writing- Review & Editing. DDLZ: Writing- Review & Editing. LMA: Conceptualization, Methodology, Writing- Review & Editing, Supervision.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This study was approved by the University of Miami Institutional Review Board and Jackson Health System Clinical Research Review Committee (CRRC) and a waiver of informed consent was granted.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

References

1. Centers for Disease Control. Coronavirus Disease 2019 (COVID-19) in the U.S. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html. Accessed September 27, 2020.
2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507-13.
3. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Welein C, Stark H, Tazankov A, Wi WW, Li VW, Mentzer SJ, Jonigk D. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020;DOI:1010156/NEJMoa2015432 [Epub ahead of print].
4. Brune K, Frank J, Schwingshackl A, Finigan J, Venkataramana, SK. Pulmonary epithelial barrier function: some new players and mechanisms. Am J Physiol Lung Cell Mol Physiol 2015;308(8): L731-L745.
5. Siddiqi HK and Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart and Lung Transplant 2020;39(5):405-7.
6. Zhang C, Wu Z, Li JW, Zhao H, Wang G. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020;55(5):105954.
7. Coomes EA and Haghbayan H. Interleukin-6 in COVID-19: A systematic review and meta-analysis.
8. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor t cell-induced severe or life-threatening cytokine release syndrome. Oncologist 2018;23(8):943-947.

9. Giamarellos-Bourboulis EJ, et al. et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020;27(6):992-1000.e3.

10. Alzghari SK and Acuna VS. Supportive treatment with tocilizumab for COVID-19: a systematic review. J Clin Virol 2020;127:104380.

11. Luo P, Liu Y, Qiu L, Lui X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 2020;92(7):814-8.

12. Xu X, Mingfeng H, Tiantian L, Sun W, Wang D, Fu B, Zhou W, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. Proc Natl Acad Sci USA 2020;117(20):10970-5.

13. Sciascia S, Apra F, Baffa A, Baldovino S, Boara D, Boero R, Bonora S, Calcagno A, Cecchi I, Cinnirella G, Converso M, Cozzi M, Crosasso P, De Iaco F, Perri GD, Eandi M, Fenoglio R, Giusti M, Imperiale D, Imperiale G, Livigni S, Manno E, Massara C, Milone V, Natale G, Navarra M, Oddone V, Osella S, Piccioni P, Radin M, Roccatello D, Rossi D. Pilot prospective open, single arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumato 2020;38(3):529-32.

14. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, Cossi S. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med 2020; 76:31-5.

15. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, Zhou N, Petty LA, Baang JH, Dollman NO, Frame D, Gregg KS, Kaul DR, Nagel J, Patel TS, Zhou S, Lauring AS, Hanauer DA, Martin E, Sharma P, Fung CM, Pogue JM. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. medRxiv 2020;DOI:10.1101/2020.05.29.20117358. (preprint)

16. Price CC, Altice FL, Shyr MY, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen S-C, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee Al, LoRusso PM, Topal JE, Cruz CD, Malinis M. Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-10 patients: survival and clinical outcomes. Chest 2020;DOI:10.1016/j.chest.2020.06.006.(In press)

17. Guaraldi G, Meschiari M, Gozzi-Lepri A, Milic J, Tonelli R, Menozzi M, Franceschini R, Cuomo G, Orlando G, Borghi V, Santoro A, Di Gaetano M, Puzzolante C, Carli F, Bedini A, Corradi L, Fantini R, Castaniere I, Tabbi L, Giryards M, Tedeschi S, Gianella M, Bartoletti M, Pascale R, Dolci G, Brugiono L, Pietrangelo A, Cossarizza A, Pea F, Cline E, Salvarani C, Massari M, Viale PL, Mussini C. Tocilizumab in patients with severe COVID-10: a retrospective cohort study. Lancet Rheumatol 2020;2(8):e474-84. DOI:10.1016/S2665-9913(20)30173-9. (Epub ahead of print)

18. Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S Sinclaire BA, Bednarz U, Marafelias M, Hansen E, Siegel DS, Goy AH, Pecora AL, Sawczuk I, Koniaris LS, Simwenyi M, Varga DW, Tank K, Stein AA, Allusson V, Lin GS, Oser WF, Ruma RA, Reichman J, Brusco Jr L, Carpenter KL, Costanzo EJ, Vivona V, Goldberg SL. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre
observational study. Lancet Rheumatol 2020;2(10):e603-2. DOI:10.1016/S2665-9913(20)30173-9. (Epub ahead of print)
19. Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zhend Z, Rose-John S, White JC, Nazimuddin F, Wetheim G, Levine BL, June CH, Porter DL, Grupp SA. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov 2016;6(6):664-679.
20. China's National Health Commission. Novel Coronavirus Treatment Guidelines – 7th Edition. 2020.
21. Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB. Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. Chest 2007;132,410-417.
22. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camorota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-2533.
23. World Health Organization. WHO R&D Blueprint novel Coronavirus: COVID-19 Therapeutic Trial Synopsis. 2020.
24. ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia (EMPACTA). Available from https://clinicaltrials.gov/ct2/show/NCT04372186. Accessed September 27, 2020.
25. ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab in Hospitalized Participants With Severe COVID-19 Pneumonia (REMDACTA). Available from https://clinicaltrials.gov/ct2/show/NCT04409262. Accessed September 27, 2020.
26. Lippi G and Plebani M. Laboratory abnormality in patients with COVID-2019 infection. Clin Chem Lab Med 2020;58(7):1131-4.
27. Actemra (tocilizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; 2020.
28. Nishimoto N, et al. Mechanisms and pathologic significance in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959-64.
29. Rimland CA, Morgan CE, Bell GJ, Kim MK, Hedrick T, Marx A, Bramson B, Swygard H, Napravnik S, Schmitz JL, Carson SS, Fischer WA, Eron JJ, Gay CL, Parr JB. Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center. medRxiv 2020;DOI:10.1101/2020.05.13.20100404. (preprint)
30. Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, Tomelleri A, Baldissera E, Rovere-Querini P, Ruggeri A, Monti G, De Cobelli F, Zangrillo A, Tresoldi M, Castagna A, Dagna L. Efficacy and safety of tocilizumab in severe in COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med 2020;76:43-9.
31. Kimmig LM, Wu D, Gold M, Pettit NN, Pitrik D, Mueller J, Husain AN, Mutlu EA, Mutlu GM. IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. medRxiv 2020;DOI:10.1101/2020.05.15.20103531. (preprint)
32. Horby P, Lim WS, Emberson J, Mafmam M, Bell J, Linsell L, Staplin N, Brightling C, Ustanowski A, Elmah E, Prudon B, Green C, Felton T, Chadwich D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery
K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ, RECOVERY Collaborative Group. medRxiv 2020;DOI:10.1101/2020.06.22.20137273. (preprint)
33. Navarro G, Taroumian S, Barroso N, Duan L, Furst D. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical outcomes. Semin Arthritis Rheum 2014;43(4):458-69.
34. Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, Riddell SR, Maloney DG, Boeckh M, Turtle CJ. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 2018;131(1):121-30.

Tables

Table 1. Patient characteristics
|                                    | All (N=60) | Died (n=9) |
|------------------------------------|------------|------------|
| Age, median (range), years         | 54 (26-87) | 58 (33-84) |
| Male, n (%)                        | 40 (66.7)  | 8 (88.9)   |
| Ethnicity                          |            |            |
| Hispanic                           | 38 (63.3)  | 6 (66.7)   |
| Black                              | 14 (23.3)  | 2 (22.2)   |
| White                              | 7 (11.7)   | 1 (11.1)   |
| Asian                              | 1 (1.7)    | 0 (0.0)    |
| Comorbidities                      |            |            |
| Obese (BMI >30)                    | 35 (58.3)  | 6 (66.7)   |
| Hypertension                       | 32 (53.3)  | 8 (88.9)   |
| Diabetes                           | 15 (25.0)  | 3 (33.3)   |
| Congestive heart failure           | 4 (6.7)    | 1 (11.1)   |
| Coronary artery disease            | 1 (1.7)    | 0 (0.0)    |
| Asthma                             | 4 (6.7)    | 0 (0.0)    |
| COPD                               | 1 (1.7)    | 1 (11.1)   |
| Obstructive sleep apnea            | 2 (3.3)    | 0 (0.0)    |
| HIV                                | 1 (1.7)    | 0 (0.0)    |
| Transplant                         | 1 (1.7)    | 0 (0.0)    |
| Concomitant therapies              |            |            |
| Hydroxychloroquine                 | 52 (86.7)  | 8 (88.9)   |
| Corticosteroids                    | 32 (53.3)  | 5 (55.6)   |
| Inhaled nitric oxide               | 5 (8.3)    | 1 (11.1)   |
| Intravenous immunoglobulin (IVIG)  | 4 (6.6)    | 0 (0.0)    |
| Tacrolimus                         | 2 (3.3)    | 1 (11.1)   |
| Convalescent plasma                | 2 (3.3)    | 0 (0.0)    |
| Plasmapheresis                     | 1 (1.7)    | 0 (0.0)    |
| Time from symptom onset to hospital admission, median (range), days | 6 (1-14)   | 7 (1-14)   |
| Time from hospital admission to receiving tocilizumab, median (range), days  | 2 (0-12)   | 1 (0-4)    |
| days                        | Time from symptom onset to receiving tocilizumab, median (range), days |
|---------------------------|------------------------------------------------------------------------|
|                           | 8 (1-21)                                                               |
|                           | 8 (1-15)                                                               |

Table 2. Clinical presentation on day of tocilizumab administration
| Disease severity                                      | n (%) |
|-------------------------------------------------------|-------|
| **WHO Ordinal Scale**                                 |       |
| 8 (deceased)                                          | 0 (0.0) |
| 7 (invasive mechanical ventilation + organ support)   | 17 (28.3) |
| 6 (invasive mechanical ventilation)                   | 9 (15.0) |
| 5 (non-invasive ventilation or high-flow oxygen)       | 24 (40.0) |
| 4 (oxygen by mask or nasal prongs)                    | 1 (1.7) |
| 3 (hospitalized without oxygen therapy)               | 0 (0.0) |
| 1-2 (not hospitalized)                                |       |
| **Temperature ≥38°C**                                 | 28 (46.7) |
| **Heart rate ≥100 beats/min**                          | 34 (56.7) |
| **Respiratory rate ≥30 breaths/min**                   | 36 (60.0) |
| **Abnormal chest imaging**                            | 59 (98.3) |
| **Vasopressor use**                                   | 18 (30.0) |
| **Renal replacement therapy**                          | 4 (6.7) |
| **Use of paralytics**                                  | 9 (15.0) |
| **Proned**                                             | 5 (8.3) |
| Room air                                              | 1 (1.7) |
| Nasal cannula                                         | 18 (30.0) |
| Venti-mask                                             | 3 (5.0) |
| Nonrebreather                                          | 7 (11.7) |
| High-flow nasal cannula                                | 6 (10.0) |
| Non-Invasive Positive Pressure Ventilation            | 2 (3.3) |
| Invasive mechanical ventilation                       | 23 (38.3) |
| **ARDS**                                              |       |
| Mild (201<PaO₂/FiO₂≤300)                              | 13 (21.7) |
| Moderate (101<PaO₂/FiO₂≤200)                          | 21 (35.0) |
| Invasive mechanical ventilation                       | 16 (26.7) |
| Parameter                                      | Median (range) | Reference values | Number of patients with available data |
|-----------------------------------------------|----------------|------------------|----------------------------------------|
| Severe (PaO$_2$/FiO$_2$ ≤ 100)                |                |                  |                                        |
| PaO$_2$/FiO$_2$, median (range)               | 166 (33-523)   |                  |                                        |
| SOFA score, median (range)                    | 3 (0-11)       |                  |                                        |
| ICU care                                      | 45 (75.0)      |                  |                                        |
| Laboratory parameters                         |                |                  |                                        |
| White blood cell count, x10$^9$/L              | 9 (2.7-29.6)   | 4.0-10.5         | 51                                      |
| Absolute neutrophil count, x10$^9$/L          | 6.85 (1.8-26.8)| 2.0-6.0          | 49                                      |
| Absolute lymphocyte count, x10$^9$/L          | 0.8 (0.2-2.6)  | 1.1-2.7          | 48                                      |
| Neutrophil-to-lymphocyte ratio (NLR)          | 7.56 (2.25-62)| 0.88-4$^a$       | 48                                      |
| Hemoglobin, g/dL                              | 12.7 (9-15.9)  | 11.1-14.6        | 51                                      |
| RDW-CV, %                                     | 14 (11.6-18.3) | 11-15            | 51                                      |
| Platelets, x10$^9$/L                          | 240 (101-513)  | 140-400          | 49                                      |
| Sodium, mmol/L                                | 135 (123-148)  | 135-145          | 53                                      |
| CO$_2$, mmol/L                                | 24 (11-36)     | 22-30            | 53                                      |
| AST, U/L                                      | 70.5 (25-711)  | 15-46            | 46                                      |
| ALT, U/L                                      | 51.5 (6-242)   | 9-52             | 46                                      |
| Total bilirubin                               | 0.65 (0.2-2.4) | 0.2-1.3          | 48                                      |
| Creatinine, mg/dL                             | 0.88 (0.4-4.58)| 0.66-1.25        | 53                                      |
| Interleukin-6, pg/mL                          | 133.9 (8.73-2160.69)| none      | 26                                      |
| C-reactive protein, mg/dL                     | 24.2 (3.2-45)  | 0.0-0.9          | 49                                      |
| Erythrocyte sedimentation rate, mm/hr         | 50 (18-102)    | 0-10             | 24                                      |
| Lactate dehydrogenase, U/L                    | 1333 (477-5089)| 313-618          | 47                                      |
| Ferritin, ng/mL                               | 1412.5 (45-29304)| 30-400     | 46                                      |
| Procalcitonin, ng/mL                          | 0.40 (0.027-16.34)| 0-0.08   | 33                                      |
| D-dimer, mcg/mL | 1.3 (0.4->20) | 0.49 | 33 |
|----------------|--------------|------|----|
| Troponin, ng/mL| 0.104 (<0.012-7.21) | 0.034 | 15 |

Note: abnormal medians highlighted in bold

\(^a\) Luo H, et al. *Clin Lab* 2019;65(3).

Table 3. Outcomes within 30 days of receiving tocilizumab
| Clinical improvement                        | 36/60 (60.0) |
|--------------------------------------------|-------------|
| Mortality                                  | 9/60 (15.0) |
| Time to death from receiving tocilizumab, median (range), days | 6 (1-14)   |
| Discharged alive                           | 33/60 (55.0) |
| Hospital length of stay for those discharged alive, median (range), days | 15 (0-32) |
| Required ICU care                          | 52/60 (86.7) |
| Remained admitted to ICU at day 30          | 13/52 (25.0) |
| Step down to floor at day 30                | 5/52 (9.6) |
| Discharged from hospital alive by day 30    | 25/52 (48.1) |
| Died by day 30                              | 9/52 (17.3) |
| Required invasive mechanical ventilation    | 29/60 (48.3) |
| Successful extubation, n (%)                | 13/29 (44.8) |
| Duration of mechanical ventilation for those extubated, median (range), days | 15 (6-35) |
| Infectious complications                   | 16/60 (26.7) |
| Time to first infection, median (range), days | 10.5 (2-28) |
| Cultures drawn while in ICU, n (%)          | 26/29 (89.7) |
| Cultures drawn while intubated, n (%)       | 25/29 (86.2) |
| Receiving concomitant steroids, n (%)       | 10/16 (62.5) |
| Type of suspected infection, n (%)          |             |
| Respiratory                                | 14/29 (48.3) |
| Bacteremia                                 | 13/29 (44.8) |
| Fungemia                                   | 1/29 (3.4) |
| Urinary tract infection                    | 1/29 (3.4) |